In benign lesions, this degradation undergoes an imbalance, whereas in the tumor tissue it is possible to observe the migration of NRF2 to the nucleus, where this factor acts in response to oxidative stress, thus activating antioxidant enzymes [20,22]. Here, NFE2L2 is linked to neoplasm.